These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
496 related articles for article (PubMed ID: 19219507)
1. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Jung SY; Han W; Lee JW; Ko E; Kim E; Yu JH; Moon HG; Park IA; Oh DY; Im SA; Kim TY; Hwang KT; Kim SW; Noh DY Ann Surg Oncol; 2009 May; 16(5):1112-21. PubMed ID: 19219507 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer. Matsubara N; Mukai H; Itoh K; Nagai S Oncology; 2011; 81(5-6):345-52. PubMed ID: 22248824 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
4. A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. Sun JM; Han W; Im SA; Kim TY; Park IA; Noh DY; Heo DS; Bang YJ; Choe KJ; Kim NK Cancer; 2004 Dec; 101(11):2516-22. PubMed ID: 15517588 [TBL] [Abstract][Full Text] [Related]
6. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A; Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514 [TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients]. Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207 [TBL] [Abstract][Full Text] [Related]
8. The importance of prognostic factors in premenopausal women with breast cancer. Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE; J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of breast conservation therapy for breast cancer in Hong Kong: prognostic impact of ipsilateral breast tumor recurrence and 2005 St. Gallen risk categories. Yau TK; Soong IS; Chan K; Chan M; Cheung P; Lau HW; Chang AT; Lee AW Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):667-72. PubMed ID: 17379441 [TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer. Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172 [TBL] [Abstract][Full Text] [Related]
12. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Harbeck N; Dettmar P; Thomssen C; Berger U; Ulm K; Kates R; Höfler H; Jänicke F; Graeff H; Schmitt M Br J Cancer; 1999 May; 80(3-4):419-26. PubMed ID: 10408848 [TBL] [Abstract][Full Text] [Related]
13. Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy. Garassino I; Gullo G; Orefice S; Tondulli L; Masci G; Salvini P; Eboli M; Di Tommaso L; Giordano L; Alloisio M; Roncalli M; Santoro A Breast; 2009 Aug; 18(4):263-6. PubMed ID: 19682903 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of c-erbB2 expression in breast cancer. Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S J Surg Oncol; 2002 Apr; 79(4):216-23. PubMed ID: 11920778 [TBL] [Abstract][Full Text] [Related]
15. Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer: a prospective study on 675 patients. Marrelli D; Pinto E; Neri A; Megha T; Gioffrè W; Cioppa T; De Marco G; De Stefano A; Roviello F Oncol Rep; 2006 Feb; 15(2):425-9. PubMed ID: 16391864 [TBL] [Abstract][Full Text] [Related]
16. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome. Geara FB; Nasr E; Tucker SL; Charafeddine M; Dabaja B; Eid T; Abbas J; Salem Z; Shamseddine A; Issa P; El Saghir N Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):364-9. PubMed ID: 17324529 [TBL] [Abstract][Full Text] [Related]
17. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer. Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432 [TBL] [Abstract][Full Text] [Related]
18. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study]. Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497 [TBL] [Abstract][Full Text] [Related]
19. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225 [TBL] [Abstract][Full Text] [Related]
20. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]